Intelligent Nanovector Delivery System
Legal Citation
Summary of the Inventive Concept
A novel system integrating nanovectors for targeted delivery of active substances with cutting-edge technologies such as AI, IoT, blockchain, and novel materials to enhance efficacy, safety, and transparency.
Background and Problem Solved
The original patent on nanovectors for delivering active substances in the body had limitations in terms of real-time monitoring, personalized treatment, and secure tracking. The new inventive concept addresses these limitations by synergistically combining the patented nanovectors with distinct technologies.
Detailed Description of the Inventive Concept
The Intelligent Nanovector Delivery System comprises a nanovector according to claim 1, a wearable IoT device for real-time monitoring and adjustment of active substance delivery, an AI-powered module for personalized treatment planning, a blockchain-based platform for secure tracking, and a biodegradable coating made of a novel, biocompatible material. The system enables targeted delivery, real-time monitoring, and secure tracking of nanovectors, ensuring enhanced efficacy, safety, and transparency.
Novelty and Inventive Step
The new claims introduce the innovative combination of nanovectors with AI, IoT, blockchain, and novel materials, which is non-obvious and novel compared to the original patent. The integration of these distinct technologies enables a more powerful and efficient system for targeted delivery of active substances.
Alternative Embodiments and Variations
Alternative embodiments may include the use of different AI algorithms, various IoT devices, or alternative blockchain platforms. Variations may also include the incorporation of other novel materials or the integration of additional technologies, such as robotics or augmented reality.
Potential Commercial Applications and Market
The Intelligent Nanovector Delivery System has significant commercial potential in the pharmaceutical and biotechnology industries, particularly in the areas of targeted cancer treatment, gene therapy, and vaccine development. The system's enhanced efficacy, safety, and transparency make it an attractive solution for healthcare providers and patients alike.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K38/31 |
| A | A61 | A61K9/146 |
| A | A61 | A61K31/704 |
| A | A61 | A61K33/243 |
| A | A61 | A61K33/244 |
| A | A61 | A61K47/6929 |
| A | A61 | A61K49/0002 |
| A | A61 | A61K49/128 |
| A | A61 | A61K49/1881 |
| A | A61 | A61P35/00 |
| B | B82 | B82Y5/00 |
| A | A61 | A61K9/0019 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Nanomedicine, drug delivery systems, medical nanotechnology with focus on targeted pharmaceutical vector design and advanced medical technologies
Person of Ordinary Skill (PHOSITA) Profile
A PhD-level researcher with expertise in nanotechnology, materials science, and biomedical engineering, familiar with interdisciplinary approaches to drug delivery and medical technology integration
Obviousness Rationale
A PHOSITA would recognize that integrating monitoring technologies and advanced computational methods with nanovector delivery represents a natural progression of existing nanotechnology approaches. The combination of IoT, AI, and blockchain with nanovector technology follows predictable engineering design patterns for enhancing medical treatment precision and tracking. These technological integrations represent incremental improvements that would be obvious to a skilled practitioner seeking to optimize drug delivery systems.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,604 |
|---|---|
| Title | Nanovectors and uses |
| Assignee(s) | NH THERAGUIX |